People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
Experts express enthusiasm after US health regulators approved the first new form of treatment for schizophrenia in decades.
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
Benzinga on MSN7h
FDA Approves First Novel Schizophrenia Drug in 70 Years, Impacting Up to 3 Million Patients in the USThe FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback